Ignite Creation Date:
2024-07-17 @ 11:12 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06488950
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-27
Brief Title:
A Study on TIL for the Treatment of Advanced Solid Tumors
Sponsor:
Shanghai Juncell Therapeutics
Organization:
Shanghai Juncell Therapeutics
Study Overview
Official Title:
A Study on Tumor Infiltrating Lymphocytes for the Treatment of Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte TIL therapy in patients with advanced solid tumors Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused iv into the patient after NMA lymphodepletion treatment with hydroxychloroquine600mgsingle-dose and cyclophosphamide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None